SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992; 80: 879886.
  • 2
    Raffo AJ, Perlman H, Chen M-W, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995; 55: 44384445.
  • 3
    Stattin P, Damber J-E, Karlberg L, Nordgren H, Bergh A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res. 1996; 24: 257264.
  • 4
    Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate. 1997; 3: 915.
  • 5
    McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 69406944.
  • 6
    Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993; 143: 390400.
  • 7
    Apakama I, Robinson MC, Walter NM, et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 1996; 74: 12581262.
  • 8
    Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 1996; 2: 389398.
  • 9
    Szende B, Romics I, Torda I, Bély M, Szegedi Zs, Lovász S. Apoptosis, mitosis, p53, bcl2, ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. Urol Int. 1999; 63: 115119.
  • 10
    Kajiwara T, Takeuchi T, Ueki T, et al. Effect of bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol. 1999; 6: 520525.
  • 11
    Westin P, Lo P, Marin CM, et al. Bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int J Oncol. 1997; 10: 113118.
  • 12
    Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology. 1999; 54: 3646.
  • 13
    Miyake H, Tolcher A, Gleave ME. Antisense bcl-2 oligodeoxynucleotides inhibit progression in androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999; 59: 40304034.
  • 14
    Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol. 1996; 148: 15571565.
  • 15
    Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 1996; 120: 159166.
  • 16
    Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol. 1997; 158: 22782283.
  • 17
    Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. P53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999; 162: 20402045.
  • 18
    Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and e-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 162: 12381243.
  • 19
    Theodorescu D, Broder SF, Boyd JC, Mills SE, Frierson HF Jr. P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997; 158: 131137.
  • 20
    Borre M, Stausbøl-Grøn B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol. 2000; 164: 716721.
  • 21
    Bylund A, Stattin P, Widmark A, Bergh A. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol. 1998; 49: 143148.
  • 22
    Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998; 52: 10851090.
  • 23
    Scherr DS, Vaughan ED Jr., Wei J, et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999; 162: 1217.
  • 24
    Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001; 165 (6 Pt 1): 2126–2130.
  • 25
    Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993; 74: 609619.
  • 26
    Li X, Marani M, Yu J, et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res. 2001; 61: 186191.
  • 27
    Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74: 597608.
  • 28
    Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med. 1995; 182: 821828.
  • 29
    Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA. 1995; 92: 78347838.
  • 30
    Clarke MF, Apel IJ, Benedict MA, et al. A recombinant bcl-Xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA. 1995; 92: 1102411028.
  • 31
    Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996; 148: 15671576.
  • 32
    Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of bcl-2, bax, and p53 in high grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate. 1998; 37: 223229.
  • 33
    Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith DR. Prostate tumors from an Asian population: examination of bxa, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer. 2000; 83: 761768.
  • 34
    Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000; 97: 38503855.
  • 35
    Royela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000; 18: 135146.
  • 36
    Cowen D, Troncoso P, Khoo VS, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002; 8: 11481154.
  • 37
    Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000; 18: 39043911.
  • 38
    BeahrsOH, HensonDE, HutterRVP, KennedyBJ, editors. AJCC manual for staging of cancer, 4th edition. Philadelphia: JB Lippincott Company, 1992: 181183.
  • 39
    Khoo VS, Pollack A, Cowen D, et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate. 1999; 41: 166172.
  • 40
    Pollack A, Wu CS, Czerniak B, et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997; 3: 18231829.
  • 41
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 42
    Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, Inc., 1991: 5125.
  • 43
    Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984: 110120.
  • 44
    Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer. 1999; 82: 846852.
  • 45
    Hendry JH, Potten CS. Intestinal cell radiosensitivity: a comparison for cell death assayed by apoptosis or by a loss of clonogenicity. Int J Radiat Biol Relat Stud Phys Chem Med. 1982; 42: 621628.
  • 46
    Lim Joon D, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997; 38: 10711077.
  • 47
    Kyprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer. 1997; 70: 341348.
  • 48
    Pollack A, Ashoori F, Sikess C, et al. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys. 1999; 46: 153158.
  • 49
    Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys. 2001; 51: 10021007.
  • 50
    Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 1991; 67: 879888.
  • 51
    Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. P53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998; 51: 346351.
  • 52
    Rakozy C, Grignon DJ, Sarkar FH, Sakr WA, Littrup P, Forman J. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod Pathol. 1998; 11: 892899.
  • 53
    Grossfeld GD, Olumi AF, Connolly JA, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998; 159: 14371443.
  • 54
    Bruckheimer EM, Cho S, Brisbay S, et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene. 2000; 19: 24042412.
  • 55
    Buckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene. 2000; 19: 52515258.